Follow @keithspeights
Recent articles
Why Hill-Rom Holdings' Q1 Results Were Better Than They Appear at First Glance
The medical technology company's flat year-over-year revenue growth doesn't tell the full story.
Why eHealth Shares Are Crushing It Today
Investors really like the company's sneak peek at its Q4 results, which are scheduled to be officially announced next month.
Why CBD Stocks Could Soon Skyrocket
Big news could be on the way.
How NextGen Healthcare Beat Expectations in Q3
The healthcare technology company topped Wall Street estimates on both its top and bottom lines in the third quarter.
Why Karuna Therapeutics Shares Sank Today
The biotech's biggest shareholder just made a move that rattled Karuna's other shareholders.
Why Autolus Therapeutics Shares Are Plunging Today
Investors are reacting negatively to the biotech's public stock offering.
The 2 Big Obstacles for Marijuana Stocks: Mitch McConnell and Joe Biden
The two politicians from different parties are united on at least one front: their opposition to legalizing pot.
Why Novavax Shares Are Sinking Today
Yesterday's euphoria that a virus scare could boost the biotech's fortunes has given way to a more realistic assessment of what's going on.
Here's Why Investors Really Liked Abbott Labs' Q4 Earnings Results
The healthcare giant delivered a solid quarterly performance yet again, with sales growth in all of its segments.
Aurora Cannabis: Love It or Leave It?
This beaten-down marijuana stock is a lightning rod among investors.
How Much Is Amarin Really Worth?
Opinions vary considerably.
Why BioCryst Pharmaceuticals Stock Is Jumping Today
Worries about the spread of a virus in China are driving the biotech's shares higher.
How PetMed Express Dropped the Ball With Its Q3 Results
The online pet pharmacy topped analysts' earnings estimates but missed on the top line.
Why Novavax Stock Is Skyrocketing Today
Concern about a new virus in China is providing a big catalyst for this biotech.
Does Canopy Growth's Cannabis 2.0 Delay Really Matter?
The big Canadian cannabis producer won't launch its new beverage products on time. Is it a big deal or nothing to worry about?
What Aphria's and Organigram's Quarterly Updates Mean for Aurora Cannabis and Canopy Growth
There's good news and there's bad news.
1 Picture You Need to See Before Writing Off GW Pharmaceuticals
The cannabis-focused biotech's presentation at the J.P. Morgan Healthcare Conference was eye-opening.
3 Attractive Dividend Stocks Whose Dividends Could Double
And it could happen in five years or less.
3 Big Winners From the "Super Bowl of Healthcare"
These stocks skyrocketed during healthcare's biggest event of the year -- the J.P. Morgan Healthcare Conference.
Better Buy: Abbott Laboratories vs. AbbVie
Which stock wins in a matchup between these two healthcare siblings?